Skip to content

Firefly ANKLE Sprain Study

Firefly ANKLE Sprain Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02307955
Enrollment
24
Registered
2014-12-04
Start date
2014-09-30
Completion date
2016-01-31
Last updated
2016-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grade I/II Ankle Sprain

Brief summary

The device to be tested (fireflyTM) stimulates the common peroneal nerve and causes the foot to twitch, and has been shown to increase blood flow. The device is also indicated for the treatment of oedema. In this study the investigators intend to assess the use of the device as an adjunctive therapy for people recovering from grade 1 and 2 ankle sprains.

Interventions

DEVICEfirefly
OTHERStandard of care

Sponsors

Firstkind Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged 18 years and over 2. Referred to physiotherapy for treatment of ankle sprain 3. Clinical diagnosed ankle sprain with evidence of swelling 4. Able to understand the Subject Information Sheet and willing to sign the written Informed Consent Form. 5. Able and willing to follow the protocol requirements

Exclusion criteria

1. Has an ankle sprain grade 3 2. Evidence of fracture 3. Has a pacemaker 4. Chronic Obesity (BMI Index \>40kg/m2). 5. Pregnancy. 6. History or signs of previous deep or superficial vein thrombosis/pulmonary embolism. 7. Varicosities, ulceration or erosion around the area of the leg where the study device would be fitted 8. Not able to fit firefly device

Design outcomes

Primary

MeasureTime frame
Oedema lower leg1 week
FAAM ankle function measure1 week

Secondary

MeasureTime frame
Ankle proprioception - as assessed by the time that the participant can stand on one leg for with their eyes closed, this will be recorded and repeated three times, the average will be taken1 week
VAS Pain score1 week
Adverse event rate1 week

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026